Executive Summary

An Investigational New Drug (IND) application for a viral vector therapy is built upon auditable documentation that substantiates the product’s quality, consistency, and control. For US East Coast sponsors, delays often originate in the Chemistry, Manufacturing, and Controls (CMC) section. Common challenges include characterizing the vector capsid, verifying vector genome integrity, and quantifying process-related impurities. A proactive documentation strategy, initiated at the earliest stages of development, is the most effective method for meeting an 18-24 month timeline to IND.

Aligning Vector Manufacturing Data with Regulatory Expectations

The integrity of an IND submission for an AAV or lentiviral therapeutic rests on the quality of its supporting CMC documentation. For these complex biologics, Module 3 of the eCTD presents a distinct set of challenges. Every data point, from the qualification of multiple plasmid starting materials to the analytical characterization of the final purified vector, must be captured and contextualized within a GxP framework.

Our approach, executed within a >100,000 sq ft facility, integrates documentation into the development process from the start. This methodology has been a key factor for the programs we have supported, which have maintained a 100% IND success rate since 2019, even as the Franklin Biolabs brand itself launched in 2024.

Learn More: Watch the full video on Diversifying the Value Chain

From Component Control to Submission-Ready Modules

A defensible IND package provides a clear, data-driven justification for the proposed clinical trial. This requires a documentation system that connects the quality of individual raw materials with the performance and stability of the final viral vector. The ability to demonstrate a sustained biological effect is directly tied to a well-controlled and well-documented manufacturing process.

Key documentation pillars for viral vector therapies include:

• Raw Material & Starting Material Qualification: Complete traceability and quality verification for all materials, including the plasmid DNA constructs and the producer cell bank.

• Vector Product Characterization: Detailed reports on the identity, quality, purity (e.g., empty/full capsid ratio), and potency of the final purified vector.

• Process Development Reports: Records of the upstream (e.g., transfection, infection) and downstream (e.g., chromatography, filtration) processes, with justification for selected parameters.

• Analytical Method Qualification: Phase-appropriate qualification or validation reports for all assays used for product release, including vector titer, infectivity, and impurity profiles.

• Batch Records & Stability Data: Comprehensive manufacturing records for all batches, supported by a robust, ongoing stability program under intended storage conditions.

This structured approach ensures that the necessary data is organized to meet regulatory expectations, minimizing the risk of delays.